Page 1

( Mark One ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 OR 1934 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF FORM 10 - K Delaware ( State of organization ) MACROGENICS , INC . ( Exact name of registrant ) Title of each class Common stock , par value $ 0.01 per For the transition period from Commission File Number 001-36112 share to 9704 Medical Center Drive , Rockville , Maryland 20850 ( Address of principal executive offices and zip code ) ( 301 ) 251-5172 ( Registrant's telephone number ) Securities registered pursuant to Section 12 ( b ) of the Act : Trading Symbol ( s ) 06-1591613 ( I.R.S. Employer Identification Number ) MGNX Name of each exchange on which registered Nasdaq Global Select Market Securities registered pursuant to Section 12 ( g ) of the Act : None Indicate by check mark if the registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15 ( d ) of the Exchange Act . Yes No ✔ Indicate by check mark whether the registrant ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the registrant was required to file such reports ) and ( 2 ) has been subject to such filing requirements for the past 90 days . Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T during the preceding 12 months ( or for such shorter period that the registrant was required to submit such files ) . Yes No